Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study

por Wang, Michael, Ramchandren, Radhakrishnan, Chen, Robert, Karlin, Lionel, Chong, Geoffrey, Jurczak, Wojciech, Wu, Ka Lung, Bishton, Mark, Collins, Graham P., Eliadis, Paul, Peyrade, Frédéric, Lee, Yihua, Eckert, Karl, Neuenburg, Jutta K., Tam, Constantine S.
Publicado 2021

Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial

por Minnema, Monique C., Nasserinejad, Kazem, Hazenberg, Bouke, Hegenbart, Ute, Vlummens, Philip, Ypma, Paula F., Kröger, Nicolaus, Wu, Ka Lung, Kersten, Marie Jose, Schaafsma, M. Ron, Croockewit, Sandra, de Waal, Esther, Zweegman, Sonja, Tick, Lidwien, Broijl, Annemieke, Koene, Harry, Bos, Gerard, Sonneveld, Pieter, Schönland, Stefan
Publicado 2019

S197: LINKER-MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

por Lee, Hans C., Bumma, Naresh, Richter, Joshua, Dhodapkar, Madhav, Hoffman, James E., Suvannasankha, Attaya, Zonder, Jeffrey, Shah, Mansi R., Lentzsch, Suzanne, Maly, Joseph J., Ye, Jing Christine, Wu, Ka Lung, Deveaux, Michelle, Chokshi, Dhruti, Boyapati, Anita, Hazra, Anasuya, Lorenc, Karen Rodriguez, Kroog, Glenn, Houvras, Yariv, Jagannath, Sundar
Publicado 2023

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

por Dimopoulos, Meletios A., Lonial, Sagar, White, Darrell, Moreau, Philippe, Weisel, Katja, San-Miguel, Jesus, Shpilberg, Ofer, Grosicki, Sebastian, Špička, Ivan, Walter-Croneck, Adam, Magen, Hila, Mateos, Maria-Victoria, Belch, Andrew, Reece, Donna, Beksac, Meral, Spencer, Andrew, Oakervee, Heather, Orlowski, Robert Z., Taniwaki, Masafumi, Röllig, Christoph, Einsele, Hermann, Matsumoto, Morio, Wu, Ka Lung, Anderson, Kenneth C., Jou, Ying-Ming, Ganetsky, Alex, Singhal, Anil K., Richardson, Paul G.
Publicado 2020

P877: IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE...

por Groen, Kaz, Stege, Claudia, Nasserinejad, Kazem, de Heer, Koen, van Kampen, Roel J.W., Leys, Rineke B.L., Thielen, Noortje, Westerman, Matthijs, Wu, Ka-Lung, Ludwig, Inge, Issa, Djamila E., Velders, Gerjo A., Vekemans, Marie-Christiane, van de Donk, Niels W.C.J., Timmers, Gert-Jan, de Boer, Fransien, Tick, Lidwine W., van der Spek, Ellen, de Waal, Esther G.M., Sohne, Maaike, Sonneveld, Pieter, Nijhof, Inger S., Klein, Saskia K., Levin, Mark-David, Ypma, Paula F., Zweegman, Sonja
Publicado 2023

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial

por Groen, Kaz, Stege, Claudia A.M., Nasserinejad, Kazem, de Heer, Koen, van Kampen, Roel J.W., Leys, Rineke B.L., Thielen, Noortje, Westerman, Matthijs, Wu, Ka-Lung, Ludwig, Inge, Issa, Djamila E., Velders, Gerjo A., Vekemans, Marie-Christiane, Timmers, Gert-Jan, de Boer, Fransien, Tick, Lidwine W., Verbrugge, Annelies, Buitenhuis, Danny, Cunha, Sonia M., van der Spek, Ellen, de Waal, Esther G.M., Sohne, Maaike, Sonneveld, Pieter, Nijhof, Inger S., Klein, Saskia K., van de Donk, Niels W.C.J., Levin, Mark-David, Ypma, Paula F., Zweegman, Sonja
Publicado 2023